4 ms·
The sad part of this story is how this publicly funded research is being licensed to Novartis.
by guelo 13y ago
The sad part of this story is how this publicly funded research is being licensed to Novartis.
- lsh 13y ago... or how the published research will only be available from behind pay walls - if at all.
- refurb 13y agoWhy is that bad? If I had a promising new drug, I'd want someone with years of experience in getting a drug approved helping me out and the billions in capital to get it done wouldn't hurt either (which of course is available because Novartis sold a number of profitable drugs). The professor who came up with this science is going to get a cut of that, as will the university.